CGS-9896 |
|
| ATC code | |
|---|
|
2-(4-chlorophenyl)-1H-pyrazolo[4,5-c]quinolin-3-one
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C16H10ClN3O |
|---|
| Molar mass | 295.73 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
C1=CC=C2C(=C1)C3=C(C=N2)C(=O)N(N3)C4=CC=C(C=C4)Cl
|
InChI=1S/C16H10ClN3O/c17-10-5-7-11(8-6-10)20-16(21)13-9-18-14-4-2-1-3-12(14)15(13)19-20/h1-9,19H N Key:QCBUAKLOWCOUCR-UHFFFAOYSA-N N
|
| NY (what is this?) (verify) |
CGS-9896 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.[1]
CGS-9896 is a benzodiazepine receptor partial agonist which produces long-lasting anxiolytic and anticonvulsant effects in animal studies but does not produce sedative effects.[2][3] It also increases appetite,[4] and reduces the development of gastrointestinal ulcers following chronic stress.[5]
References
- ^ Leidenheimer NJ, Schechter MD (Oct 1988). "Discriminative stimulus properties of CGS 9896: interactions within the GABA/benzodiazepine receptor complex". Pharmacol Biochem Behav. 31 (2): 249–54. doi:10.1016/0091-3057(88)90342-5. PMID 2854261. S2CID 21773709.
- ^ Bernasconi R, Marescaux C, Vergnes M, et al. (1988). "Evaluation of the anticonvulsant and biochemical activity of CGS 8216 and CGS 9896 in animal models". J Neural Transm. 71 (1): 11–27. doi:10.1007/BF01259406. PMID 3343593. S2CID 31525533.
- ^ Rump S, Raszewski W, Gidynska T, Galecka E (1990). "Effects of CGS 9896 in acute experimental intoxication with fluostigmine". Arch. Toxicol. 64 (5): 412–3. Bibcode:1990ArTox..64..412R. doi:10.1007/BF01973465. PMID 2206111. S2CID 19084019.
- ^ Chen SW, Davies MF, Loew GH (1995). "Food palatability and hunger modulated effects of CGS 9896 and CGS 8216 on food intake". Pharmacol Biochem Behav. 51 (2–3): 499–503. doi:10.1016/0091-3057(95)00020-W. PMID 7667375. S2CID 32809713.
- ^ Najim RA, Karim KH (Feb 1990). "Effect of CGS 9896 on stress-induced gastric ulcer in rat". Clin Exp Pharmacol Physiol. 17 (2): 157–161. doi:10.1111/j.1440-1681.1990.tb01298.x. PMID 2109664. S2CID 37492286.
|
|---|
| 5-HT1ARTooltip 5-HT1A receptor agonists | |
|---|
| GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators | |
|---|
Gabapentinoids (α2δ VDCC blockers) | |
|---|
| Antidepressants | |
|---|
Sympatholytics (Antiadrenergics) |
- Alpha-1 blockers (e.g., prazosin)
- Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine)
- Beta blockers (e.g., propranolol, atenolol, betaxolol, nadolol, oxprenolol, pindolol)
|
|---|
| Others | |
|---|
|
|
|---|
| Alcohols | |
|---|
| Barbiturates | |
|---|
| Benzodiazepines | |
|---|
| Carbamates | |
|---|
| Flavonoids |
- 6-Methylapigenin
- Ampelopsin (dihydromyricetin)
- Apigenin
- Baicalein
- Baicalin
- Catechin
- EGC
- EGCG
- Hispidulin
- Linarin
- Luteolin
- Rc-OMe
- Skullcap constituents (e.g., baicalin)
- Wogonin
|
|---|
| Imidazoles | |
|---|
| Kava constituents |
- 10-Methoxyyangonin
- 11-Methoxyyangonin
- 11-Hydroxyyangonin
- Desmethoxyyangonin
- 11-Methoxy-12-hydroxydehydrokavain
- 7,8-Dihydroyangonin
- Kavain
- 5-Hydroxykavain
- 5,6-Dihydroyangonin
- 7,8-Dihydrokavain
- 5,6,7,8-Tetrahydroyangonin
- 5,6-Dehydromethysticin
- Methysticin
- 7,8-Dihydromethysticin
- Yangonin
|
|---|
| Monoureides | |
|---|
| Neuroactive steroids | |
|---|
| Nonbenzodiazepines | |
|---|
| Phenols | |
|---|
| Piperidinediones | |
|---|
| Pyrazolopyridines | |
|---|
| Quinazolinones | |
|---|
| Volatiles/gases | |
|---|
| Others/unsorted |
- 3-Hydroxybutanal
- α-EMTBL
- AA-29504
- Alogabat
- Avermectins (e.g., ivermectin)
- Bromide compounds (e.g., lithium bromide, potassium bromide, sodium bromide)
- Carbamazepine
- Chloralose
- Chlormezanone
- Clomethiazole
- Darigabat
- DEABL
- Deuterated etifoxine
- Dihydroergolines (e.g., dihydroergocryptine, dihydroergosine, dihydroergotamine, ergoloid (dihydroergotoxine))
- DS2
- Efavirenz
- Etazepine
- Etifoxine
- Fenamates (e.g., flufenamic acid, mefenamic acid, niflumic acid, tolfenamic acid)
- Fluoxetine
- Flupirtine
- Hopantenic acid
- KRM-II-81
- Lanthanum
- Lavender oil
- Lignans (e.g., 4-O-methylhonokiol, honokiol, magnolol, obovatol)
- Loreclezole
- Menthyl isovalerate (validolum)
- Monastrol
- Nicotinic acid
- Nicotinamide
- Org 25,435
- Phenytoin
- Propanidid
- Retigabine (ezogabine)
- Safranal
- Seproxetine
- Stiripentol
- Sulfonylalkanes (e.g., sulfonmethane (sulfonal), tetronal, trional)
- Terpenoids (e.g., borneol)
- Topiramate
- Valerian constituents (e.g., isovaleric acid, isovaleramide, valerenic acid, valerenol)
|
|---|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |